Characteristic | Albendazole (n = 88) | Placebo (n = 90) |
Demographic information | ||
Age (y) (mean (SE)) | 39.39 (17.79) | 41.55 (16.80) |
Children (<18 y) (No (valid %)) | 8 (9.2) | 7 (8.0) |
Males (No (valid %)) | 51 (58.6) | 46 (52.9) |
Females (No (valid %)) | 36 (41.4) | 41 (47.1) |
Missing age and gender information (n) | 1 | 3 |
Cyst phase and location | ||
Active cysts (No (valid %)) | 59 (68.6) | 57 (66.3) |
Transitional (No (valid %)) | 49 (57.0) | 54 (66.8) |
Calcifications (No (valid %)) | 38 (44.2) | 32 (37.2) |
Parenchymal cysts (No (valid %)) | 74 (86.0) | 74 (82.2) |
Active parenchymal cysts | 45 (52.3) | 39 (45.3) |
Transitional parenchymal cysts | 40 (46.5) | 52 (60.5) |
Calcified parenchymal cysts | 35 (40.7) | 31 (36.0) |
Extraparenchymal cysts (No (valid %)) | 35 (40.7) | 42 (48.8) |
Active extraparenchymal cysts | 28 (32.6) | 30 (34.9) |
Transitional extraparenchymal cysts | 11 12.8) | 13 15.1) |
Calcified parenchymal cysts | 7 (8.1) | 7 (8.1) |
Missing baseline scan (n) | 2 | 4 |
Most common symptoms | ||
Headache (No (valid %)) | 60 (68.2) | 64 (71.1) |
Seizures (No (valid %)) | 51 (59.3) | 56 (64.4) |
Dizziness (No (valid %)) | 16 (18.6) | 28 (32.2) |
Gait problems (No (valid %)) | 13 (15.1) | 17 (19.5) |
Limb weakness (No (valid %)) | 13 (15.1) | 9 (10.3) |
Depression and/or anxiety (No (valid %)) | 15 (15.1) | 17 (19.5) |
*Categories are not mutually exclusive; patients may have had cysts of more than one type and in more than one location and may have experienced multiple symptoms.